License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2015

Sanofi [Member]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

During the three months ended March 31, 2014, the Company recognized revenue based on the following components of the Sanofi Agreement:

	Three months ended March 31,
(in thousands)	2014
Upfront payment	$	1,250
Milestone payments		521
Development services		10,700
Manufacturing services and other		563
Total		13,034

As of December 31, 2014, the Company maintained the following assets and liabilities related to the Sanofi Agreement:

(in thousands)	December 31, 2014
Accounts receivable, billed	$	369
Accounts receivable, unbilled		1,282
Deferred revenue		—

Baxter [Member]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

As of March 31, 2015 and December 31, 2014, the Company maintained the following assets and liabilities related to the Baxter Agreement:

(in thousands)	March 31, 2015		December 31, 2014
Accounts receivable, billed	$	1,615	$	—
Accounts receivable, unbilled		2,600		1,615
Deferred revenue		78,914		91,156